BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NeuroAiD II (MLC901) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NeuroAiD II (MLC901)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07828210-760@assetmemo.bio
DTSTAMP:20261121T004527Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:NeuroAiD II (MLC901): Phase 4 readout est. (NCT07828210)
DESCRIPTION:NeuroAiD II (MLC901)\, phase 4.\nStudy: NeuroAiD Patient-Report
 ed Outcomes in Patients With Mild to Moderate Ischemic Stroke\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/mlc901#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07828210
URL:https://assetmemo.bio/drug/mlc901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191028-760@assetmemo.bio
DTSTAMP:20261121T004527Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:NeuroAiD II (MLC901): Phase 3 readout est. (NCT07191028)
DESCRIPTION:NeuroAiD II (MLC901)\, phase 3\, Alzheimer's Disease.\nStudy: A
 lzheimer's Disease THErapy With NEuroaid II\nEstimated primary completion:
  February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mlc90
 1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 191028
URL:https://assetmemo.bio/drug/mlc901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
